Readable research linked to original sources

Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

2 articles

Newest first

Research Article 2026CC BYFree full text

Central Blockade of Cannabinoid CB1 and CB2 Receptors Increases Force Generation in Reserpine-Treated Mice, but Only CB1 Blockade Extends the Duration of Effort

Beatriz Carminati dos Santos, Izabely Guedes da Rosa, Laíze de Freitas Mazzardo, Naiara de Souza Santos, Izabel Feltrin Fabro, Tatyana Nery +2 more

Motor impairment in parkinsonism extends beyond the classical triad to weakness and a reduced capacity to sustain motor output, whose neuromodulatory control is poorly resolved. The endocannabinoid system is a candidate regulator, but CB1 and CB2 receptors have not been separated within one preparation. Reserpine-treated adult female Swiss mice received vehicle, the CB1 antagonist AM251, or the CB2 antagonist AM63…

ACS Pharmacology & Translational Science PubMed Central Open Access

Open article record in new tab ↗

Research Article 2016CC BYFree full text

Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats.

Fernanda F. Peres, Raquel Levin, Mayra A. Suiama, Mariana C. Diana, Douglas A. Gouvêa, Valéria Almeida +8 more

Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson's disease patients, CBD is able to attenuate the psychotic symptoms induced by L-DOPA and to improve quality of life. Repeated administration of reserpine in rodents induces motor impairments that are accompanied by cognitive deficits, and ha…

Frontiers in Pharmacology PubMed Central Open Access

Open article record in new tab ↗